Related Experiment Videos
MLH3 mutation in endometrial cancer
Nicholas P Taylor1, Matthew A Powell, Randall K Gibb
1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, 4911 Barnes-Jewish Hospital Plaza, St. Louis, MO 63110, USA. taylorni@wustl.edu
Cancer Research
|August 4, 2006
Summary
The DNA mismatch repair gene MLH3 may play a role in endometrial cancer. Researchers found inherited variants and somatic mutations in MLH3 in endometrial tumors, suggesting its involvement in cancer development.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- MLH3 is a DNA mismatch repair gene linked to MLH1.
- Its role in colorectal cancer is debated, prompting investigation into other cancers.
Purpose of the Study:
- To investigate the role of MLH3 in endometrial tumorigenesis.
- To analyze tumor and germ line DNA from high-risk endometrial cancer patients.
Main Methods:
- Analyzed DNA from 57 endometrial cancer patients excluding those with known MSH2, MSH6, or MLH1-methylated tumors.
- Used single-strand conformational variant analysis to identify MLH3 variants.
- Performed combined bisulfite restriction analysis for MLH3 promoter methylation.
Main Results:
- Identified 16 MLH3 variants, including 12 missense changes.
- Found three somatic MLH3 mutations in 57 tumors.
- Observed a germ line missense variant with loss of heterozygosity (LOH) in one patient's tumor.
- No evidence of MLH3 promoter methylation was found.
Conclusions:
- MLH3 alterations, including inherited variants and somatic mutations, suggest a role in endometrial tumorigenesis.
- Further research is warranted to clarify MLH3's specific function in endometrial cancer development.